UNSPSC 51101940: Cycloguanil embonate

This classification denotes an antimalarial and folic acid antagonist with the molecular formula C23H16O6.2C11H14ClN5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier TCO0SY4N3D, chemically known as 4,6-diamino-1-(p-chlorophenyl)-1,2-dihydro-2,2-dimethyl-s-triazine pamoate but more generally known as cycloguanil embonate, which bears US NIH Compound Identifier 11870. European Medicines Agency schedules Cycloguanil embonate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06853MIG.

World Health Organization schedules cycloguanil embonate in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations schedule cycloguanil embonate under HS 29336980 and SITC 51576. SMILES: CC1(N=C(N=C(N1C2CCC(CC2)CL)N)N)C.CC1(N=C(N=C(N1C2CCC(CC2)CL)N)N)C.C1CCC2C(C1)CC(C(C2CC3C4CCCCC4CC(C3O)C(=O)O)O)C(=O)O

UNSPSC 51101940 Cycloguanil embonate is a Commodity code for a specific antimalarial pharmaceutical active ingredient, yet the recent state and local procurement activity tagged under this code does not reflect actual purchasing of cycloguanil embonate itself. Instead, the opportunities show state and local health agencies procuring finished pharmaceutical products — antibiotic tablets through warehouse piggyback arrangements and naloxone/drug deactivation systems through direct competitive bid — that bear no direct relationship to the code's nominal scope. The mismatch suggests either miscategorization in the source data or that cycloguanil embonate procurement, if occurring at state and local level, is not currently visible in recent solicitations.

The Illinois Department of Public Health awarded a $2,999,999.11 piggyback contract through MMCAP Infuse to Chartwell Rx LLC on August 28, 2026, for Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets under an Invitation for Bid process, while Seminole County, Florida posted an IFB on June 30, 2026, for 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026. The code shows minimal recent activity relevant to its stated scope, with the available opportunities concentrated in Florida and Illinois and focused on finished-goods pharmaceutical procurement rather than active pharmaceutical ingredients like cycloguanil embonate.